In addition, through in vitro and in vivo experiments, we found that DCA can specifically inhibit glycolysis-dependent tumor growth, and tumors with high levels of PDHX Lys 488 acetylation are the suitable target of DCA drugs (Fig. 5C–H). This evidence concerns the gene PDHX and neoplasm.